IP Library › Granted Patent US 12708624
Granted Patent B2
US 12708624 · App. 17/926,114 · Granted Aug 18, 2026

Methods of treating pulmonary fibrosis

Inventors: Chris Burns (Melbourne, AU); John Lambert (Melburne, AU); Mark Graeme Devlin (Melbourne, AU)
Assignee: Amplia Therapeutics Limited
A61K31/506A61P11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12708624
App. No.
17/926,114
Granted
Aug 18, 2026
Kind
B2
Abstract

A method of treating or preventing pulmonary fibrosis in a patient in need thereof by administering a FAK inhibitor defined by formula I or a pharmaceutically acceptable derivative thereof to said patient: (I)

Claims (4)

1 . A method of treating or preventing pulmonary fibrosis in a patient in need thereof by administering a FAK inhibitor defined by formula I or a pharmaceutically acceptable salt thereof to said patient:

2 . The method of claim 1 wherein said salt is a tartrate salt.

3 . The method of claim 1 wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

4 . The method of claim 1 wherein the pulmonary fibrosis is associated with infection with a coronavirus.